Ronald Mancini, MD
Ophthalmic Plastic and Reconstructive Surgery · Calabasas, CANPI 1457307639
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Amgen at 50.1% of the total. 2025 is the largest year on record at $454, 7.8 times the $58 reported in 2021. That places this record below the midpoint for ophthalmic plastic and reconstructive surgery clinicians in CA, where the typical reported total is $1,399.
Across 11 payments — averaging $75.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$417
- Biotissue Holdings Inc.$216
- Revance Therapeutics, Inc.$149
- Merz Pharmaceuticals, LLC$35
- Harrow Eye, LLC$15
What the payments were for
- Food & beverage$833100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 6 | $417 |
| Biotissue Holdings Inc. | 2 | $216 |
| Revance Therapeutics, Inc. | 1 | $149 |
| Merz Pharmaceuticals, LLC | 1 | $35 |
| Harrow Eye, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$833 in reported general payments places this provider in the 35th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.
See all ophthalmic plastic and reconstructive surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 12 | $8,554 |
| ErythromycinErythromycin Base | 97 | $1,294 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 63 | $688 |
| MoxifloxacinMoxifloxacin Hcl | 18 | $475 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Calabasas
- Marjan FaridIrvine$742K
- Jeffrey JosephNewport Beach$292K
- Sandy Zhang-NunesLos Angeles$149K
- Soheab UgradarLos Angeles$131K
- Andrea KosslerStanford$91K
- Nicolas BiroWest Covina$76K
- Joseph ChangBakersfield$74K
- Anupam JayaramMenlo Park$26K
- Charles KimStockton$21K
- Omar OzgurMission Viejo$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.